The deal is expected to close in late Q2 2025, subject to Nevro shareholder and regulatory approval.Globus Medical also reaffirmed its guidance for 2025 net sales of $2.66B to $2.69B and non-GAAP ...

Globus Medical will acquire Nevro for $250 million in cash, enhancing its musculoskeletal technology portfolio andglobal marketreach. Globus Medical and Nevro Corp. have agreed on an all-cash ...

Since November, shares of Globus Medical have displayed continued momentum ... net cash holdings of $270 million, although that Nevro operates with a modest net cash position, but the real ...

Globus Medical closed 2024 on a strong note with record financial performance, driven by sales growth, innovative product launches, and strategic acquisitions. The integration of Nevro Corporation ...

As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor ...

citing the company’s impressive performance and potential synergies from its recent acquisition of Nevro Corp. This acquisition is anticipated to influence Globus Medical’s 2025 financial ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Globus Medical (GMED – Research Report) and Nevro Corp (NVRO – Research Report). See what stocks are receiving ...

2025 Financial Guidance and Fourth-Quarter 2024 Earnings Conference Call and Webcast As previously announced on February 6, 2025, given the pending acquisition of Nevro by Globus Medical ...

Globus Medical's results underscore a strong quarter ... This outlook could improve further if the pending acquisition of Nevro (purchased for $250 million earlier this month) is finalized ...

BTIG responded by raising its price target for Globus Medical shares to $94, maintaining a Buy rating, citing the company’s impressive performance and potential synergies from its recent acquisition ...